KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $4.14.

  • Jazz Pharmaceuticals' EPS (Basic) rose 1828.57% to $4.14 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.97, marking a year-over-year decrease of 11302.01%. This contributed to the annual value of $9.08 for FY2024, which is 3869.78% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its EPS (Basic) stood at $4.14 for Q3 2025, which was up 1828.57% from -$11.74 recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year EPS (Basic) high stood at $4.14 for Q3 2025, and its period low was -$11.74 during Q2 2025.
  • Its 5-year average for EPS (Basic) is -$0.05, with a median of $0.82 in 2022.
  • In the last 5 years, Jazz Pharmaceuticals' EPS (Basic) tumbled by 61296.3% in 2022 and then soared by 353333.33% in 2023.
  • Jazz Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.54 in 2021, then crashed by 612.96% to -$3.85 in 2022, then skyrocketed by 138.96% to $1.5 in 2023, then soared by 106.06% to $3.09 in 2024, then skyrocketed by 33.94% to $4.14 in 2025.
  • Its EPS (Basic) was $4.14 in Q3 2025, compared to -$11.74 in Q2 2025 and $3.09 in Q4 2024.